Immunic (NASDAQ:IMUX) Price Target Lowered to $8.00 at HC Wainwright

Immunic (NASDAQ:IMUX) had its price objective decreased by equities research analysts at HC Wainwright from $10.00 to $8.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

A number of other analysts also recently issued reports on IMUX. D. Boral Capital dropped their price objective on shares of Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Immunic in a research note on Wednesday, October 8th. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a report on Thursday, October 16th. Roth Capital began coverage on shares of Immunic in a research note on Friday, November 7th. They set a “buy” rating and a $3.00 target price on the stock. Finally, Chardan Capital began coverage on shares of Immunic in a research note on Monday, September 29th. They issued a “buy” rating and a $13.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $7.40.

Immunic Stock Up 4.1%

Shares of NASDAQ:IMUX traded up $0.03 during midday trading on Friday, reaching $0.74. 364,413 shares of the company traded hands, compared to its average volume of 1,285,254. Immunic has a 12 month low of $0.56 and a 12 month high of $1.42. The firm’s fifty day moving average price is $0.83 and its two-hundred day moving average price is $0.87. The firm has a market capitalization of $73.20 million, a price-to-earnings ratio of -0.79 and a beta of 1.53.

Immunic (NASDAQ:IMUX) last posted its earnings results on Thursday, November 13th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.05. Analysts forecast that Immunic will post -0.94 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Focus Partners Wealth increased its stake in Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock worth $2,816,000 after acquiring an additional 415,104 shares during the last quarter. Aberdeen Group plc increased its holdings in shares of Immunic by 678.1% in the 2nd quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock worth $5,750,000 after buying an additional 7,184,457 shares during the last quarter. 683 Capital Management LLC raised its position in shares of Immunic by 28.6% during the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock valued at $981,000 after buying an additional 200,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Immunic by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock valued at $3,832,000 after acquiring an additional 219,957 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in Immunic during the 3rd quarter valued at $239,000. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.